Biktarvy and Valacyclovir hydrochloride drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) and Valacyclovir hydrochloride (valacyclovir hydrochloride). Common drug interactions include back pain among females and anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Biktarvy and Valacyclovir hydrochloride. It is created by eHealthMe based on reports of 60 people who take the same drugs from the FDA, and is updated regularly.

What is Biktarvy?

Biktarvy has active ingredients of bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. It is often used in hiv infection. eHealthMe is studying from 19,543 Biktarvy users. Check the latest studies of Biktarvy.

What is Valacyclovir hydrochloride?

Valacyclovir hydrochloride has active ingredients of valacyclovir hydrochloride. It is often used in herpes zoster. eHealthMe is studying from 12,929 Valacyclovir hydrochloride users. Check the latest studies of Valacyclovir hydrochloride.



On Jul, 26, 2026

60 people who take Biktarvy and Valacyclovir hydrochloride together, and have interactions are studied.

Biktarvy and Valacyclovir hydrochloride drug interactions.

What are the common drug interactions of Biktarvy and Valacyclovir Hydrochloride, by gender? *:

female:

  1. Back pain
  2. Blood creatinine increased
  3. Bone loss
  4. Bone pain
  5. Decreased activity
  6. Foot fracture
  7. Fractured sacrum
  8. Joint range of motion decreased (disease of joint movement)
  9. Joint swelling
  10. Nephropathy (damage to or disease of a kidney)

male:

  1. Anxiety
  2. Emotional distress
  3. Renal failure (kidney dysfunction)
  4. Gait disturbance
  5. Hypertension (high blood pressure)
  6. Insomnia (sleeplessness)
  7. Renal impairment (severely reduced kidney function)
  8. Arthralgia (joint pain)
  9. Bone pain
  10. Mobility decreased (ability to move is reduced)

What are the common drug interactions of Biktarvy and Valacyclovir Hydrochloride, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Hospitalisation

30-39:

  1. Drug resistance (reduction in effectiveness of a drug)
  2. Anxiety
  3. Chronic kidney disease
  4. Depression
  5. Emotional distress
  6. Pain
  7. Pollakiuria (abnormally frequent passage of relatively small quantities or urine)
  8. Pulmonary embolism (blockage of the main artery of the lung)
  9. Thrombosis (formation of a blood clot inside a blood vessel)

40-49:

  1. Quality of life decreased
  2. Bone disorder
  3. Bone loss
  4. Decreased activity
  5. Drug ineffective
  6. Fanconi syndrome acquired (self developed genetic disease of kidney damage due to defective transport system)
  7. Femur fracture
  8. Hypokalaemia (low potassium)
  9. Immune system disorder
  10. Impaired work ability

50-59:

  1. Emotional distress
  2. Pain
  3. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  4. Anxiety
  5. Osteopenia (a condition where bone mineral density is lower than normal)
  6. Osteoporosis (bones weak and more likely to break)
  7. Blood creatinine increased
  8. Chronic kidney disease
  9. Renal failure (kidney dysfunction)
  10. Anaemia (lack of blood)

60+:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Bone pain
  4. Osteoporosis (bones weak and more likely to break)
  5. Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
  6. Back pain
  7. Balance disorder
  8. Blood creatinine increased
  9. Chronic kidney disease
  10. Clavicle fracture

What are the existing conditions these people have? *

  1. Pain: 6 people, 10.00%
  2. Insomnia (sleeplessness): 6 people, 10.00%
  3. Mycobacterium Avium Complex Infection: 4 people, 6.67%
  4. Viral Infection: 3 people, 5.00%
  5. Kaposi's Sarcoma (a tumour caused by human herpes virus): 3 people, 5.00%
  6. Diarrhea: 3 people, 5.00%
  7. Depression: 3 people, 5.00%
  8. Bacterial Infection: 3 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Biktarvy and Valacyclovir hydrochloride?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Biktarvy and Valacyclovir hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Biktarvy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Valacyclovir hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Biktarvy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Valacyclovir hydrochloride and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate and valacyclovir hydrochloride (the active ingredients of Biktarvy and Valacyclovir hydrochloride, respectively), and Biktarvy and Valacyclovir hydrochloride (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: